国家医保局部署药品集采工作 提出“四三四四”要求

2019-01-27 决策者说 国家医疗保障局

1月25日,国家组织药品集中采购和使用试点实施工作部署会在北京召开。

1月25日,国家组织药品集中采购和使用试点实施工作部署会在北京召开。此次会议主题是深入贯彻中央深改委会议和国务院常务会议精神,认真落实《国务院办公厅关于印发国家组织药品集中采购和使用试点方案的通知》(国办发〔2019〕2号,以下称2号文)要求,全面部署推进试点实施有关工作。国家医保局副局长、国家组织药品集中采购和使用试点工作小组办公室主任陈金甫同志出席并讲话。

陈金甫强调,党中央、国务院高度重视人民群众的健康福祉,十九大以来,针对"看病贵"、"药价贵"问题推出了一整套"组合拳",国家组织药品集中采购和使用试点是"组合拳"的重要组成部分,既是降低虚高药价、提升群众获得感的民生工程,更是全面深化改革的政治任务,也是围绕主要问题和关键环节,探索药品招采机制和以市场为主导的价格形成机制创新的改革举措,意义重大。

陈金甫要求,各地要全面准确把握试点方案要求,针对药品招采中长期存在的"招采分离"、"量价不挂钩"、"用不管价"等问题,深刻剖析问题本质,找出体制机制的症结,抓住改革窗口期、打出有力组合拳,着力实现"四联三通":联盟采购、量价联动、招标-采购-使用联动、支付和利益机制联动,体制打通、政策打通、部门联通,达到"四个促进":促进药价回归合理水平、促进医药产业健康发展、促进临床用药水平的提高、促进医疗机构收入结构和医保支出结构腾笼换鸟。

目前,试点已进入结果执行和政策落地阶段,对于各地推进试点实施工作,陈金甫强调,各地要提高政治站位,加强组织领导,树立改革精神,立足全局谋划。要做好统筹协调,完善工作机制,试点办负责对试点全过程进行指导监督,将细化各部门分工,促进部门协调联动。联采办在操作层面组织并督促各试点城市执行采购结果。试点城市要根据统一安排,对标对表完成各项实施工作,要科学设定实施方案,深入落实试点各项政策,重点做到"四个确保":确保质量、确保供应、确保使用、确保回款。要做好舆论引导,加强风险防范,制定舆论风险评估与管控方案,加强正面宣传引导,做好医务人员的宣传引导和培训工作,确保试点工作平稳运行。

会上,国家医保局价格招采司司长钟东波对2号文进行了全面解读。国家卫生健康委医政医管局副局长焦雅辉就集中采购中选药品的使用工作作了具体部署,要求试点地区卫生健康部门畅通优先使用中选药品的政策通道,督促公立医疗机构按照约定的采购量优先采购和使用中选药品,确保1年内完成合同用量。国家药监局药品监督管理司副巡视员徐胜敏介绍了中选药品质量监管工作,强调全面落实药品监管"四个最严"要求,以监督检查和产品抽检为抓手,加强药品生产和流通使用监管,从严实施药品抽检和不良反应监测,切实保障药品质量安全。北京、天津、上海、重庆等11个试点城市及所在省有关部门负责同志参加会议。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1735510, encodeId=83da1e355105f, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Mon Feb 04 09:48:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359496, encodeId=c92435949626, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Jan 29 09:06:06 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280468, encodeId=dbc712804681a, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405888, encodeId=b9f11405888ab, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416533, encodeId=843814165333d, content=<a href='/topic/show?id=c6a98e51396' target=_blank style='color:#2F92EE;'>#药品集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87513, encryptionId=c6a98e51396, topicName=药品集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=500a3204386, createdName=songbq, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497221, encodeId=9eb1149e221cd, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
    2019-02-04 xsm929
  2. [GetPortalCommentsPageByObjectIdResponse(id=1735510, encodeId=83da1e355105f, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Mon Feb 04 09:48:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359496, encodeId=c92435949626, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Jan 29 09:06:06 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280468, encodeId=dbc712804681a, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405888, encodeId=b9f11405888ab, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416533, encodeId=843814165333d, content=<a href='/topic/show?id=c6a98e51396' target=_blank style='color:#2F92EE;'>#药品集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87513, encryptionId=c6a98e51396, topicName=药品集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=500a3204386, createdName=songbq, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497221, encodeId=9eb1149e221cd, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
    2019-01-29 183****7028

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1735510, encodeId=83da1e355105f, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Mon Feb 04 09:48:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359496, encodeId=c92435949626, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Jan 29 09:06:06 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280468, encodeId=dbc712804681a, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405888, encodeId=b9f11405888ab, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416533, encodeId=843814165333d, content=<a href='/topic/show?id=c6a98e51396' target=_blank style='color:#2F92EE;'>#药品集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87513, encryptionId=c6a98e51396, topicName=药品集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=500a3204386, createdName=songbq, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497221, encodeId=9eb1149e221cd, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1735510, encodeId=83da1e355105f, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Mon Feb 04 09:48:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359496, encodeId=c92435949626, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Jan 29 09:06:06 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280468, encodeId=dbc712804681a, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405888, encodeId=b9f11405888ab, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416533, encodeId=843814165333d, content=<a href='/topic/show?id=c6a98e51396' target=_blank style='color:#2F92EE;'>#药品集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87513, encryptionId=c6a98e51396, topicName=药品集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=500a3204386, createdName=songbq, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497221, encodeId=9eb1149e221cd, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
    2019-01-29 chg122
  5. [GetPortalCommentsPageByObjectIdResponse(id=1735510, encodeId=83da1e355105f, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Mon Feb 04 09:48:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359496, encodeId=c92435949626, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Jan 29 09:06:06 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280468, encodeId=dbc712804681a, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405888, encodeId=b9f11405888ab, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416533, encodeId=843814165333d, content=<a href='/topic/show?id=c6a98e51396' target=_blank style='color:#2F92EE;'>#药品集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87513, encryptionId=c6a98e51396, topicName=药品集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=500a3204386, createdName=songbq, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497221, encodeId=9eb1149e221cd, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1735510, encodeId=83da1e355105f, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Mon Feb 04 09:48:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359496, encodeId=c92435949626, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Tue Jan 29 09:06:06 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280468, encodeId=dbc712804681a, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405888, encodeId=b9f11405888ab, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416533, encodeId=843814165333d, content=<a href='/topic/show?id=c6a98e51396' target=_blank style='color:#2F92EE;'>#药品集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87513, encryptionId=c6a98e51396, topicName=药品集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=500a3204386, createdName=songbq, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497221, encodeId=9eb1149e221cd, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Tue Jan 29 02:48:00 CST 2019, time=2019-01-29, status=1, ipAttribution=)]

相关资讯

关于国家药品集采试点方案 官方解读来了!

国务院政策例行吹风会:国家组织药品集中采购和使用试点工作(实录)袭艳春:女士们、先生们,下午好。欢迎大家出席国务院政策例行吹风会。《国务院办公厅关于印发国家组织药品集中采购和使用试点方案的通知》正式对外发布了,大家对有关内容非常的关注,为了帮助大家更好地了解相关情况,我们今天非常高兴的邀请到国家医疗保障局副局长陈金甫先生,请他为大家介绍有关情况并回答记者朋友们的提问。出席今天吹风会的还有国家卫

区域药交所,要取代省标!?

对于药品集采中的种种问题,和游洪涛一样,全国政协委员屈谦也建议打破市场壁垒 建立全国性药品交易平台。

药品集采改革倒逼公立医院薪酬制度改革

国家组织药品集中采购和使用试点工作部署会(以下简称会议)7日在京召开,药品改革作为三医联动的重要抓手,必然推进医疗三医联动,倒逼公立医院改革提速1、《会议》有啥重点?国务院副总理、国务院医改领导小组组长孙春兰出席并讲话。她强调,要深入贯彻习近平总书记关于药品集中采购的重要指示,认真落实党中央、国务院决策部署,稳妥推进试点工作,探索完善药品集中采购机制和以市场为主导的药价形成机制,降低群众药费负

药品集采需把握好与市场共舞的节奏

2018年年尾,“4+7城市药品集中采购”可以说在整个医药行业中掀起了翻天巨浪,目前正在推动11个城市落地实施。日前,在《中国医疗保险》杂志社举办的第19期青年药政论坛上,相关专家围绕“药品集中采购及实施”做了深入的解读。小保很受教益,感觉药品集中采购与实施就像政府与市场的一种共舞,节奏的协调最重要。

国家药品集采方案发布 强调医疗机构“确保用量”

1月10日上午,中共中央政治局常委、国务院副总理韩正在医疗保障工作座谈会上强调,要做好国家组织药品集中采购和使用试点工作,切实减轻群众药费负担。时隔7天,国务院办公厅正式印发《国家组织药品集中采购和使用试点方案》(下称《方案》)。原本坊间传言“2018年中秋前后发布”的《方案》,曾引发医药产业从业者的持续关注,甚至“备受煎熬”。最终发布的《方案》中,诸多细节规定与要求,亦是对各方热议的问题进行

国家药品集采和使用方案发布 医院绩效如何考虑?

2019-01-17日,国办发〔2019〕2号《国务院办公厅关于印发国家组织药品集中采购和使用试点方案的通知》(以下简称《通知》)网上发布,对医院绩效明显带来冲击和影响,医院绩效如何应对设计。1《通知》影响医院绩效有哪些方面?(1)医保基金按相同的支付标准结算《通知》规定,对于集中采购的药品,在医保目录范围内的以集中采购价格作为医保支付标准,原则上对同一通用名下的原研药、参比制剂、通过一致性评